SCHEMBL112712

SCHEMBL112712

O=C(Nc1cccnc1)c1ccccc1N1CCNCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
KDM4E B2RXH2 1/20 0.56
MEN1 O00255 1/20 0.56
HPGD P15428 1/20 0.56
KMT2A Q03164 1/20 0.56
CYP11B2 P19099 2/20 0.55
TSHR P16473 1/20 0.52
HSD17B10 Q99714 2/20 0.50
NAMPT P43490 2/20 0.50
CHEK1 O14757 1/20 0.50
MAPK1 P28482 1/20 0.50
TRPV1 Q8NER1 1/20 0.49
HTR2C P28335 1/20 0.49
ADRB2 P07550 1/20 0.48
ADRB3 P13945 1/20 0.48
CYP11B1 P15538 1/20 0.48
LMNA P02545 1/20 0.48
HIF1A Q16665 1/20 0.48
PTPN11 Q06124 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14664001 0.88 ALDH1A1 (0.59) ALDH1A1KDM4EMEN1HPGDKMT2A
SCHEMBL27942187 0.86 PRKCI (0.53) ALDH1A1CHEK1TRPV1NPC1RAB9A
SCHEMBL7841604 0.86 ALDH1A1 (0.54) ALDH1A1KDM4EMEN1HPGDKMT2A
SCHEMBL3104621 0.81 TRPV1 (0.53) ALDH1A1KDM4EMEN1HPGDKMT2A
SCHEMBL3104629 0.81 TRPV1 (0.53) ALDH1A1KDM4EMEN1HPGDKMT2A
SCHEMBL18641222 0.80 BACE1 (0.48) ALDH1A1CHEK1HTR2CADRB2
Trifluoroacetic Acid SCHEMBL114174 0.79 BACE1 (0.58) ALDH1A1MEN1KMT2ACHEK1
SCHEMBL28596949 0.79 NAMPT (0.55) NAMPTADRB2ADRB3
SCHEMBL29998472 0.79 LMNA (0.55) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL27874715 0.78 ALDH1A1 (0.63) ALDH1A1KDM4EMEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
EP-2424858-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 ALDH1A1 1720/4885KDM4E 3738/4885MEN1 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.